
On Friday December 8th, 2023, amidst a rich end-of-year festive atmosphere, The Tartufo Restaurant in Boston was brightly lit and bustling with energy, filled with bursts of joyful laughter and cheers.

On that night, Biointron held a special customer appreciation party. This party is dedicated to appreciating new and existing clients for the long-standing support and trust, and to looking forward to further collaborations.
We were honored to invite a host of partners and peers to attend this party. Mr. Zha Changchun, the CEO of Biointron, delivered a heartfelt speech, expressing gratitude to all the guests in attendance and conveying his appreciation for the continued support from our partners and industry colleagues over the years.

At the same time, the SVP of R&D, Dr. Shi Lei, presented a detailed report on the company's current business progress. He also provided an outlook for the future, giving attendees a deeper understanding of the prospects for Biointron.

During the evening, Dr. Janice Reichert from The Antibody Society shared the latest research achievements and future development trends in the antibody industry. Her excellent presentation not only included the cutting-edge technologies of the industry but also provided an in-depth analysis and forecast of the future development of the antibody industry.

Boris Xu, Biointron’s International Business Development Director, along with all colleagues also attended the party, joining together for this unforgettable evening.

At the end of the event, Biointron’s representatives expressed heartfelt thanks to each guest and promised to continue striving in the new year to provide clients with high-quality, economic, and high-speed antibody services. This party was not just a business event but also a sincere gesture of appreciation and commitment, showcasing Biointron's celebration for our customers. We look forward to a better future together with you!
VHH half extension mechanisms like Fc fusion, albumin binding, and PEGylation to……
Learn how multivalent and bispecific VHH antibodies are engineered, their advant……
April 2026 activity saw consolidation in the ADC space, continued expansion of n……
Read on for key trends talked about during the conference: Antibody Therapeutics……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



